Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer
Miguel Reina-Campos1, Juan F Linares2, Angeles Duran2
1Cancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA; Sanford Burnham Prebys Graduate School of Biomedical Sciences, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA.
Abstract:
Increasingly effective therapies targeting the androgen receptor have paradoxically promoted the incidence of neuroendocrine prostate cancer (NEPC), the most lethal subtype of castration-resistant prostate cancer (PCa), for which there is no effective therapy. Here we report that protein kinase C (PKC)λ/ι is downregulated in de novo and during therapy-induced NEPC, which results in the upregulation of serine biosynthesis through an mTORC1/ATF4-driven pathway. This metabolic reprogramming supports cell proliferation and increases intracellular S-adenosyl methionine (SAM) levels to feed epigenetic changes that favor the development of NEPC characteristics. Altogether, we have uncovered a metabolic vulnerability triggered by PKCλ/ι deficiency in NEPC, which offers potentially actionable targets to prevent therapy resistance in PCa.
Insights
Protein kinase C (PKC)λ/ι deficiency drives neuroendocrine prostate cancer (NEPC) by upregulating serine biosynthesis. This metabolic shift fuels NEPC progression and offers potential therapeutic targets for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Background:
- Androgen receptor-targeted therapies increase neuroendocrine prostate cancer (NEPC), a lethal subtype of castration-resistant prostate cancer (PCa).
- Currently, no effective therapies exist for NEPC.
- Understanding NEPC's underlying mechanisms is crucial for developing new treatments.
Purpose of the Study:
- To investigate the role of protein kinase C (PKC)λ/ι in the development of NEPC.
- To identify metabolic alterations associated with NEPC.
- To uncover potential therapeutic targets for NEPC.
Main Methods:
- Analysis of PKCλ/ι expression in de novo and therapy-induced NEPC models.
- Investigation of serine biosynthesis pathways.
- Assessment of the mTORC1/ATF4 signaling pathway.
- Measurement of intracellular S-adenosyl methionine (SAM) levels.
- Evaluation of epigenetic modifications.
Main Results:
- PKCλ/ι is downregulated in NEPC.
- PKCλ/ι deficiency upregulates serine biosynthesis via an mTORC1/ATF4-dependent pathway.
- Metabolic reprogramming enhances cancer cell proliferation.
- Increased intracellular SAM levels promote epigenetic changes characteristic of NEPC.
Conclusions:
- PKCλ/ι deficiency represents a key metabolic vulnerability in NEPC.
- Targeting the PKCλ/ι-mediated metabolic pathway may offer a strategy to prevent therapy resistance in prostate cancer.
- This study identifies novel therapeutic targets for NEPC.
Related Concept Videos
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
What is Metabolism?
The Carbon Cycle
The Eukaryotic Promoter Region
Carbon Skeletons
Increased Body Temperature


